KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations ...
MEKanistic Therapeutics, a biotechnology company developing first-in-class precision medicines designed to overcome cancer resistance mechanisms, today announced that the U.S. Food and Drug ...
The SGLT2 inhibitor empagliflozin (Jardiance) reduced the risk of creatinine increases and acute kidney injury (AKI) even in those with an early dip in estimated glomerular filtration rate (eGFR), ...
Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...
The majority of people with advanced EGFR-mutant non-small cell lung cancer (NSCLC) receiving first-line osimertinib (Tagrisso) will respond to therapy. But acquired resistance to the tyrosine kinase ...
For many people with IgA nephropathy (IgAN), a condition in which immunoglobulin A (IgA) antibodies accumulate in the kidneys and trigger inflammation, kidney function stays stable for many years. For ...
Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results